We manufacture and market a large basket of pharmaceutical formulations across chronic and acute therapies, including generics, branded generics, specialty & complex products, over-the-counter (OTC), antiretrovirals (ARV), Active Pharmaceutical Ingredients (API), and intermediates. Our portfolio spans multiple dosage forms such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids. With billions of doses delivered annually across our key therapeutic areas like neuro-psychiatry, cardiology, gastroenterology, anti-infectives diabetology, oncology, ophthalmology, dermatology, urology, nephrology, respiratory, and more, we are helping improve access to medicine globally.
Recent Posts
- SPIL Q4FY26 Financial Results
- Press Release Sun Pharma reports Q4 & full year results for FY26
- Sun Pharma signs Definitive Agreement to Acquire Organon
- Sun Pharma launches its semaglutide injection under the brand names, Noveltreat and Sematrinity in India
- Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis
Recent Comments